Updated results of a phase I study of pasireotide (SOM230) in combination with everolimus (RAD001) in patients (pts) with advanced neuroendocrine tumors (NET).

@article{Chan2011UpdatedRO,
  title={Updated results of a phase I study of pasireotide (SOM230) in combination with everolimus (RAD001) in patients (pts) with advanced neuroendocrine tumors (NET).},
  author={Jennifer A. Chan and David P. Ryan and Charles S. Fuchs and Andrew X. Zhu and Thomas Adam Abrams and Brian Wolpin and Paige K Malinowski and Eileen Regan and Matthew H. Kulke},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={4120}
}
4120 Background: Octreotide and the mTOR inhibitor everolimus have antitumor activity in NETs. Pasireotide is a novel somatostatin analog with binding affinity to a broader range of somatostatin receptor subtypes than octreotide. We performed a phase I study to evaluate safety and feasibility of combining pasireotide and everolimus in patients with advanced NETs. METHODS Pts received escalating doses of pasireotide and everolimus. Treatment was continued until tumor progression, unacceptable… CONTINUE READING